/
Company Overview We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features. We develop and commercialize genomic tests that can personalize medicine to help improve patient diagnosis and management.
10.55% operating margin is respectable but not wide. ROIC at 19.09%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 17.5% YoY. Margins deteriorated 6.7pp alongside, both lines moving the wrong way.
ROIC dropped from 94.21% to 19.09%, capital efficiency is deteriorating. Operating margin contracted 6.7pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$36M
▼ -17.5% YoY
Net Income (TTM)
$24M
▲ +266.7% YoY
Op. Margin
9.32%
▼ -6.7pp YoY
ROIC
19.05%
▼ -75.1pp YoY
Cash Flow & Balance Sheet
FCF (FY)
$5M
▲ +45.2% YoY
Op. Cash Flow (TTM)
$5M
▲ +25.5% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$3M
3Y CAGR: +89.6%
Continue Research